title: Targeted therapy for advanced gastric cancer: A review of current status and future prospects.
abstract: In the West in particular, the vast majority of gastric cancer (GC) patients present with advanced-stage disease. Although combination chemotherapy is still the most important component of treatment for these patients, it confers a modest survival advantage. Recently, increased knowledge of the key molecular signaling pathways involved in gastric carcinogenesis has led to the discovery of specific molecular-targeted therapeutic agents. Some of these agents such as trastuzumab and ramucirumab have changed the treatment paradigm for this disease. In this paper, we will summarize the current clinical status of targeted drug therapy in the management of GC.
authors.affiliation: Ozkan Kanat, Department of Medical Oncology, Uludag University faculty of Medicine, 16059 Bursa, Turkey.
authors.forename: Ozkan
authors.initials: O
authors.lastname: Kanat
authors.affiliation: Ozkan Kanat, Department of Medical Oncology, Uludag University faculty of Medicine, 16059 Bursa, Turkey.
authors.forename: Bert
authors.initials: B
authors.lastname: O'Neil
authors.affiliation: Ozkan Kanat, Department of Medical Oncology, Uludag University faculty of Medicine, 16059 Bursa, Turkey.
authors.forename: Safi
authors.initials: S
authors.lastname: Shahda
keywords: Angiogenesis; Epidermal growth factor; Gastric cancer; Targeted therapy; Treatment